131I单克隆抗体治疗柔脑膜瘤的一项初步研究。
A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors.
作者信息
Lashford L S, Davies A G, Richardson R B, Bourne S P, Bullimore J A, Eckert H, Kemshead J T, Coakham H B
机构信息
ICRF Oncology Laboratory, Institute of Child Health, London, England.
出版信息
Cancer. 1988 Mar 1;61(5):857-68. doi: 10.1002/1097-0142(19880301)61:5<857::aid-cncr2820610502>3.0.co;2-s.
A pilot study was performed to investigate the toxicity and therapeutic effect of radiolabeled antibody administered intrathecally in patients with leptomeningeal tumors. Five patients who failed conventional therapy received between 11 mCi and 40 mCi of radiolabeled antibody. The choice of antibody varied depending on the immunophenotype of the tumor. Therapy was well tolerated generally, with minimal acute toxicity. Four of five patients achieved an objective response to treatment that has been sustained for a period varying from 7 months to 2 years. No clinical signs of chronic toxicity have been observed in patients 1 and 2 years after therapy.
开展了一项初步研究，以调查鞘内注射放射性标记抗体对柔脑膜瘤患者的毒性和治疗效果。5例传统治疗失败的患者接受了11毫居里至40毫居里的放射性标记抗体。抗体的选择根据肿瘤的免疫表型而有所不同。治疗总体耐受性良好，急性毒性极小。5例患者中有4例对治疗产生了客观反应，且反应持续了7个月至2年不等。治疗后1年和2年，未观察到患者出现慢性毒性的临床体征。
Zotero 插件